Stay updated on Soticlestat in Dup 15q and CDKL5 Disorders Clinical Trial
Sign up to get notified when there's something new on the Soticlestat in Dup 15q and CDKL5 Disorders Clinical Trial page.

Latest updates to the Soticlestat in Dup 15q and CDKL5 Disorders Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedCDKL5 disorder keyword added. Revision: v3.4.2 replaces v3.4.1.SummaryDifference0.1%

- Check20 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 in the page footer; no other content changes are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check28 days agoChange DetectedAdds glossary display and new labels 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', plus a Revision: v3.4.0; the previous 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' are removed, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page footer now shows Revision: v3.3.4 (replacing v3.3.3). This is a metadata/version label update and does not modify study information, eligibility criteria, locations, or other user-facing content.SummaryDifference0.1%

- Check63 days agoChange DetectedLocations are reorganized into a single 'Locations' section listing sites by state (CA, CO, GA, MA, MN, NY), replacing separate 'X Locations' headings. This changes how potential participants locate and contact trial sites.SummaryDifference0.7%

- Check92 days agoChange DetectedPublications description updated to state that entries are automatically filled from PubMed, and the revision label shows v3.3.2 (replacing the previous v3.2.0).SummaryDifference0.1%

Stay in the know with updates to Soticlestat in Dup 15q and CDKL5 Disorders Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Soticlestat in Dup 15q and CDKL5 Disorders Clinical Trial page.